Sponsors (2)
The bill strengthens drug‑supply preparedness and reduces shortage risks through a prioritized essential medicines list, stronger interagency coordination, and supply‑chain assessments, but it does so at the cost of added federal and industry compliance spending, potential market distortions, and increased risks around sensitive data disclosure and legal uncertainty.
Millions of patients (especially those with chronic conditions) and the hospitals that serve them will face fewer unexpected drug shortages because HHS will maintain and regularly update a national "essential medicines" list and map supply-chain vulnerabilities to prioritize procurement and mitigation.
Federal policymakers, state governments, and health systems get clearer, evidence-based information through required reports, improved interagency coordination, and clarified implementation authority (Secretary = HHS), speeding regulatory responses, targeted investments, and emergency actions.
National preparedness and security are strengthened by supply‑chain assessments (including cybersecurity and single‑supplier risks), enabling identification of public‑health and national‑security vulnerabilities and coordination with agencies like CISA.
Taxpayers and health-care stakeholders will likely face increased administrative and compliance costs—HHS must create and maintain lists and reports, and industry must collect and secure detailed supply‑chain data—which could raise federal spending or divert resources.
Collecting and sharing sensitive facility, supplier, and production data increases the risk that proprietary commercial information or critical supplier identities could be exposed or mishandled, creating commercial harm or national‑security vulnerabilities.
Publicizing a prioritized 'essential medicines' list and supplier dependencies could create market distortions—surge buying, temporary supply shocks, or disincentives for manufacturers of non‑listed drugs—and procurement pressures may disrupt existing supply relationships.
Based on analysis of 6 sections of legislative text.
Requires HHS to maintain an Essential Medicines List, assess and map supply‑chain risks for listed drugs/APIs, share information across agencies, and report findings to Congress on set timelines.
Introduced June 26, 2025 by Doris Matsui · Last progress June 26, 2025
Requires the Department of Health and Human Services to maintain an updated "Essential Medicines List" of active pharmaceutical ingredients (APIs) and finished drugs that are critical for public health, national security, or patients with chronic conditions. Directs HHS to assess supply‑chain risks for those products, map and visualize their supply chains from key starting materials to finished dosage forms, share information across federal agencies, protect sensitive data, and report findings to Congress on set timelines.